FutureHouse’s Robin multi-agent system proposes ripasudil as a new treatment candidate for dry AMD
Result confirmed
The takeaway
FutureHouse’s Robin generated the hypotheses, analyses and figures that identified ripasudil, a glaucoma drug, as a candidate for dry age-related macular degeneration.
Status
- Claim
Result confirmed
- Our reporting
- High confidence
- Verification
- Peer-reviewed
- Importance
- 3 of 5
- Last verified
- 29 September 2026
Your AI and this story
- GPT-6 AstraIn its training data
- Claude Opus 5.5In its training data
- Gemini 4 HydrogenIn its training data
- Grok 4.7In its training data
It happened before the cutoffs of all four assistants, so it can be in their training data.
Key facts
- Robin proposed enhancing RPE phagocytosis as a mechanism, then ripasudil (ROCK inhibitor) as the drug
- ABCA1 upregulated ~3× (RNA-seq follow-up proposed by Robin)
- Caveat: Robin’s analysis agent reported a 7.5× phagocytosis effect; human re-analysis of the same data gave 1.75×
- No clinical data; in vitro only
What happened
Robin chained literature-search and data-analysis agents to go from disease to mechanism to drug candidate, with human lab work in between.
Why it matters
It was an early end-to-end AI-driven discovery loop in biology. The overstated effect size is a reminder that AI analyses need human re-checking.
Sources
2 sources from 2 sites. Numbers match the chips in the text.
2 sources: 2 primary
Primary
- Robin paper (Nature, 2026)nature.com, paper
- FutureHouse: Demonstrating end-to-end scientific discovery with Robinfuturehouse.org, official
Changes
- Filed